HK1131745A1 - Neurotoxic oligomers - Google Patents
Neurotoxic oligomersInfo
- Publication number
- HK1131745A1 HK1131745A1 HK09109775.3A HK09109775A HK1131745A1 HK 1131745 A1 HK1131745 A1 HK 1131745A1 HK 09109775 A HK09109775 A HK 09109775A HK 1131745 A1 HK1131745 A1 HK 1131745A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disease
- compositions
- methods
- alleviation
- alzheimer
- Prior art date
Links
- 231100000189 neurotoxic Toxicity 0.000 title 1
- 230000002887 neurotoxic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000004849 abnormal protein aggregation Effects 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 229910001431 copper ion Inorganic materials 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21477900P | 2000-06-28 | 2000-06-28 | |
| US24217700P | 2000-10-23 | 2000-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1131745A1 true HK1131745A1 (en) | 2010-02-05 |
Family
ID=26909346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK09109775.3A HK1131745A1 (en) | 2000-06-28 | 2009-10-22 | Neurotoxic oligomers |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US7618634B2 (fr) |
| EP (1) | EP1296705B1 (fr) |
| JP (1) | JP2004501204A (fr) |
| CN (2) | CN1450908A (fr) |
| AU (2) | AU2001268828C1 (fr) |
| CA (1) | CA2413354C (fr) |
| DK (1) | DK1296705T3 (fr) |
| ES (1) | ES2389811T3 (fr) |
| HK (1) | HK1131745A1 (fr) |
| NZ (1) | NZ523428A (fr) |
| WO (1) | WO2002000245A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| WO2006014638A2 (fr) * | 2004-07-19 | 2006-02-09 | The General Hospital Corporation | Anticorps anti-oligomeres reticules de la proteine $g(b)-amyloide |
| WO2006110621A2 (fr) * | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Biomarqueurs multiplexes destines a diagnostiquer la maladie d'alzheimer chez un sujet |
| PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| AU2006337137B2 (en) | 2005-12-29 | 2012-06-14 | Tersera Therapeutics Llc | Multicyclic amino acid derivatives and methods of their use |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) * | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| WO2009048631A1 (fr) * | 2007-10-11 | 2009-04-16 | University Of Tennessee Research Foundation | PRÉPARATION D'OLIGOMÈRES Aβ RÉTICULÉS PAR COVALENCE ET PURIFIÉS ET UTILISATIONS CORRESPONDANTES |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US20110166035A1 (en) * | 2009-11-24 | 2011-07-07 | Probiodrug Ag | Novel diagnostic method |
| WO2011106732A1 (fr) | 2010-02-25 | 2011-09-01 | Wyeth Llc | Surveillance pet d'une immunothérapie dirigée contre l'aβ |
| JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
| EP2603524A1 (fr) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Protéines de liaison bêta-amyloïdes |
| US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| CA3097124A1 (fr) * | 2018-05-15 | 2019-11-21 | Bausch & Lomb Incorporated | Dispositifs ophtalmiques extractibles a l'eau |
| US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
| DE102019129221B4 (de) * | 2019-10-29 | 2022-05-12 | Chiracon Gmbh | Verfahren zur Synthese von DOPA mit einer fotolabilen Schutzgruppe und Zwischenprodukten zu dessen Herstellung |
| KR20230128606A (ko) * | 2022-02-28 | 2023-09-05 | 경상국립대학교산학협력단 | 티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물 |
| CN117024554A (zh) * | 2023-05-30 | 2023-11-10 | 中国人民解放军空军军医大学 | 一种Aβ1-42寡聚体存储液的制备方法及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2001
- 2001-06-28 ES ES01947033T patent/ES2389811T3/es not_active Expired - Lifetime
- 2001-06-28 EP EP01947033A patent/EP1296705B1/fr not_active Expired - Lifetime
- 2001-06-28 JP JP2002505026A patent/JP2004501204A/ja active Pending
- 2001-06-28 NZ NZ523428A patent/NZ523428A/en not_active IP Right Cessation
- 2001-06-28 AU AU2001268828A patent/AU2001268828C1/en not_active Ceased
- 2001-06-28 CN CN01813312A patent/CN1450908A/zh active Pending
- 2001-06-28 AU AU6882801A patent/AU6882801A/xx active Pending
- 2001-06-28 WO PCT/AU2001/000786 patent/WO2002000245A1/fr active Application Filing
- 2001-06-28 CN CN2008101298934A patent/CN101411876B/zh not_active Expired - Fee Related
- 2001-06-28 CA CA2413354A patent/CA2413354C/fr not_active Expired - Fee Related
- 2001-06-28 DK DK01947033.5T patent/DK1296705T3/da active
- 2001-06-28 US US10/312,437 patent/US7618634B2/en not_active Expired - Fee Related
-
2009
- 2009-05-14 US US12/466,094 patent/US8318171B2/en not_active Expired - Fee Related
- 2009-10-22 HK HK09109775.3A patent/HK1131745A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004501204A (ja) | 2004-01-15 |
| CA2413354A1 (fr) | 2002-01-03 |
| AU2001268828B2 (en) | 2006-07-06 |
| CN1450908A (zh) | 2003-10-22 |
| AU6882801A (en) | 2002-01-08 |
| US20090297538A1 (en) | 2009-12-03 |
| NZ523428A (en) | 2008-03-28 |
| EP1296705B1 (fr) | 2012-06-13 |
| CA2413354C (fr) | 2014-04-01 |
| WO2002000245A1 (fr) | 2002-01-03 |
| EP1296705A4 (fr) | 2005-04-20 |
| US7618634B2 (en) | 2009-11-17 |
| DK1296705T3 (da) | 2012-09-17 |
| ES2389811T3 (es) | 2012-10-31 |
| AU2001268828C1 (en) | 2006-12-14 |
| CN101411876A (zh) | 2009-04-22 |
| EP1296705A1 (fr) | 2003-04-02 |
| CN101411876B (zh) | 2013-01-16 |
| US20040013680A1 (en) | 2004-01-22 |
| US8318171B2 (en) | 2012-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1131745A1 (en) | Neurotoxic oligomers | |
| IN2006KO01346A (fr) | ||
| HK1087398A1 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
| KR100521829B1 (en) | Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases | |
| MXPA04006039A (es) | Metodo para el tratamiento de afecciones vasculares y neuronales perifericas. | |
| HUT74004A (en) | Inhibitors of beta-amyloid protein production | |
| WO2006042249A3 (fr) | Methodes et compositions de traitement de la douleur de migraine | |
| PT2527315E (pt) | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson | |
| GB0223038D0 (en) | Therapeutic compounds | |
| MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
| GB0318447D0 (en) | Therapeutic agents | |
| WO2002098444A3 (fr) | Utilisation de l'hepcidine comme regulateur de l'homeostasie ferrique | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| NO20060020L (no) | 3-fluorpiperidiner som NMDA/NR2B-antagonister | |
| WO2007132292A3 (fr) | Thérapie pour la maladie d'alzheimer | |
| WO2001053457A3 (fr) | Vaccins contre certains troubles neurodegeneratifs | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| WO2002094196A3 (fr) | Methode de traitement de cancers associes a des niveaux de her-2 eleves | |
| WO2001058476A3 (fr) | Procedes et compositions pour le traitement de la maladie d'alzheimer par le renforcement de l'activite de la plasmine ou de l'activite du type de la plasmine | |
| WO2006058720A3 (fr) | Nouveaux composes pour le traitement de troubles neurologiques | |
| RS8504A (en) | Novel cyclohexil sulphones | |
| WO1999048489A3 (fr) | Methode permettant de retarder le declenchement de la maladie d'alzheimer et de traiter ou de retarder le declenchement d'autres maladies/troubles associes a l'amylose | |
| WO2001008637A3 (fr) | Traitement du syndrome premenstruel et de la menopause | |
| HK1053609A1 (en) | Candesartan for treating migraine | |
| MXPA05009428A (es) | Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20180628 |